A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2011; you can also visit the original URL.
The file type is
The focus of the study of minimal residual disease (MRD) is to redefine the concept of remission by using more sensitive molecular techniques to detect level of disease burden below that of conventional pathology. The detection of the chimeric bcr-abl mRNA transcript in chronic myeloid leukemia (CML) is a paradigm of the use of molecular biology for clinical applications. The qualitative (yes vs no) detection of MRD is associated with a relative increase in relapse rate, and the magnitude ofpmid:11188935 fatcat:mfeezyfoprabjaq2hcaiokza6u